COVID-19 vaccines through the COVAX Advanced Market Commitment, through
our contribution of £548 million, continued leadership to close the funding gap,
and support for rapid approval of vaccines in line with international standards
of safety, quality and efficacy. We have committed to share the majority of any
future surplus vaccines from our supply with COVAX, while our commitment of
£1.65 billion over five years to Gavi, the Vaccine Alliance, will support immunisation
of children in the world’s poorest countries. And to strengthen detection of new
COVID-19 variants worldwide, our experts will also offer support in genomic
sequencing to other countries through the New Variants Assessment Platform.
• To review and reinforce the cross-government approach to biosecurity, as
part of our efforts to learn the lessons of the COVID-19 response and to build
our national resilience. Our ongoing review of responsibility for biosecurity within
government will inform future considerations relating to a revised biosecurity
strategy and potential machinery-of-government changes.
• To strengthen the UK’s preparedness for future pandemics, taking a One
Health approach. Building on the creation of the Joint Biosecurity Centre and
the National Institute for Health Protection in 2020, we will improve surveillance,
understanding and communication of emerging domestic and cross-border health
threats, including zoonoses.5 We will undertake scenario analysis and contingency
planning within the UK, including to ensure the resilience of medical supply
chains. And we will review our national stockpile of clinical countermeasures and
consumables such as personal protective equipment, expanded testing capability
and laboratory equipment, ensuring they meet the planning assumptions within
the 2020 National Risk Register.
• To reform the global health system, strengthening coherence across the
international architecture – including between health and economic institutions
– and harnessing the potential of data to improve global health surveillance.
We will seek reform of the WHO, supported by a 30% increase in UK core
funding to £340 million over the next four years. We will support stronger health
systems worldwide, with improved capacity to comply with the International
Health Regulations. To strengthen the One Health approach worldwide, we
will seek to establish a Global One Health Intelligence Hub, providing countries
and organisations with a single source of intelligence on human, animal and
environmental risks, as well as global networks of zoonotic experts and zoonotic
centres of excellence – including a centre in the UK. We will also strengthen
domestic and international efforts to combat the threat posed by increasing AMR.
• To strengthen global pandemic preparedness, building on the Prime Minister’s
five-point plan to prevent future pandemics. The UK will seek to accelerate
the development and deployment of VTDs for emerging diseases, using our
G7 presidency to cut the development and deployment of vaccines for priority
pathogens to 100 days through partnership between governments, industry
and international organisations. We will also seek to increase and improve R&D
for VTDs, including through: genomic sequencing and assessing zoonotic links;
increasing innovation in storage and deployment; and standardising clinical
trials and harnessing data. We will ensure sustainable financing for pandemic
preparedness and response, and explore a WHO-led pandemic preparedness
treaty, to improve international coordination and collaboration.
5 Diseases caused by viruses, bacteria or parasites that spread from animals to humans.
94
Integrated Review
Select target paragraph3
Connect to a paragraph
Connect to an entity
Disable highlights
Add to table of contents